

Full Portfolio Holdings* as of March 31, 2025

The value of holdings represents the market value for non-derivative positions and unrealized appreciation/(depreciation) for derivative positions.

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
BASE CURRENCY					
US DOLLAR			693,273	693,273	0.61%
COMMON STOCKS					
Eli Lilly & Co.			17,779	14,683,854	12.94%
UnitedHealth Group, Inc.			21,602	11,314,048	9.97%
Boston Scientific Corp.			52,818	5,328,280	4.70%
Merck & Co., Inc.			49,348	4,429,476	3.90%
Intuitive Surgical, Inc.			7,734	3,830,418	3.38%
Vertex Pharmaceuticals, Inc.			6,839	3,315,684	2.92%
Thermo Fisher Scientific, Inc.			6,276	3,122,938	2.75%
Johnson & Johnson			17,348	2,876,992	2.54%
Cencora, Inc.			10,179	2,830,678	2.50%
AbbVie, Inc.			13,084	2,741,360	2.42%
HCA Healthcare, Inc.			7,259	2,508,347	2.21%
AstraZeneca PLC			27,049	1,988,102	1.75%
Abbott Laboratories			14,746	1,956,057	1.72%
Waters Corp.			4,439	1,636,082	1.44%
Danaher Corp.			7,838	1,606,790	1.42%
Bristol-Myers Squibb Co.			26,208	1,598,426	1.41%
Gilead Sciences, Inc.			13,434	1,505,280	1.33%
Centene Corp.			24,340	1,477,681	1.30%
Humana, Inc.			4,529	1,198,373	1.06%
Molina Healthcare, Inc.			3,617	1,191,404	1.05%
Argenx SE			1,982	1,173,076	1.03%
ICON PLC			6,660	1,165,433	1.03%
Dexcom, Inc.			16,726	1,142,219	1.01%
Medtronic PLC			12,631	1,135,022	1.00%
Edwards Lifesciences Corp.			15,452	1,119,961	0.99%
Stryker Corp.			2,823	1,050,862	0.93%
Insulet Corp.			3,959	1,039,673	0.92%
Labcorp Holdings, Inc.			4,324	1,006,368	0.89%
Galderma Group AG			9,338	987,630	0.87%
UCB SA			5,589	984,025	0.87%
Encompass Health Corp.			9,529	965,097	0.85%
Agilent Technologies, Inc.			8,121	949,995	0.84%
Alignment Healthcare, Inc.			50,666	943,401	0.83%
Option Care Health, Inc.			26,845	938,233	0.83%
Exact Sciences Corp.			20,210	874,891	0.77%
United Therapeutics Corp.			2,802	863,773	0.76%
Novo Nordisk AS			12,343	843,993	0.74%
Elevance Health, Inc.			1,773	771,184	0.68%
Acadia Healthcare Co., Inc.			25,421	770,765	0.68%
Glaukos Corp.			7,734	761,180	0.67%

Full Portfolio Holdings* as of March 31, 2025

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Verona Pharma PLC			11,819	750,388	0.66%
LifeStance Health Group, Inc.			107,746	717,588	0.63%
Daiichi Sankyo Co. Ltd.			29,792	709,463	0.63%
Amgen, Inc.			2,268	706,595	0.62%
Alnylam Pharmaceuticals, Inc.			2,467	666,139	0.59%
GSK PLC			32,714	625,171	0.55%
Ascendis Pharma AS			3,975	619,544	0.55%
Avidity Biosciences, Inc.			20,553	606,725	0.53%
Revolution Medicines, Inc.			16,767	592,881	0.52%
Addus HomeCare Corp.			5,867	580,188	0.51%
Privia Health Group, Inc.			24,695	554,403	0.49%
Qiagen NV			13,533	543,350	0.48%
Elanco Animal Health, Inc.			48,788	512,274	0.45%
DiaSorin SpA			4,844	481,066	0.42%
Soleno Therapeutics, Inc.			6,631	473,785	0.42%
Surgery Partners, Inc.			19,682	467,448	0.41%
Natera, Inc.			3,295	465,946	0.41%
Ardent Health Partners, Inc.			31,952	439,340	0.39%
Merus NV			10,354	435,800	0.38%
Zai Lab Ltd.			11,614	419,730	0.37%
PTC Therapeutics, Inc.			8,192	417,464	0.37%
Scholar Rock Holding Corp.			12,892	414,478	0.37%
Align Technology, Inc.			2,535	402,710	0.36%
agilon health, Inc.			90,878	393,502	0.35%
Ultragenyx Pharmaceutical, Inc.			10,643	385,383	0.34%
Sarepta Therapeutics, Inc.			5,954	379,984	0.33%
Axsome Therapeutics, Inc.			3,207	374,032	0.33%
Cytokinetics, Inc.			8,884	357,048	0.31%
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.			9,436	354,817	0.31%
Bio-Techne Corp.			5,705	334,484	0.29%
Blueprint Medicines Corp.			3,748	331,735	0.29%
Evolent Health, Inc.			34,930	330,787	0.29%
Nuvalent, Inc.			4,657	330,274	0.29%
Vaxcyte, Inc.			8,224	310,538	0.27%
Xenon Pharmaceuticals, Inc.			9,163	307,419	0.27%
Akero Therapeutics, Inc.			7,581	306,879	0.27%
Hologic, Inc.			4,939	305,082	0.27%
Apogee Therapeutics, Inc.			8,049	300,711	0.27%
Disc Medicine, Inc.			5,996	297,641	0.26%
Crinetics Pharmaceuticals, Inc.			8,611	288,813	0.25%
Kymera Therapeutics, Inc.			8,725	238,803	0.21%
Apellis Pharmaceuticals, Inc.			10,844	237,158	0.21%
Structure Therapeutics, Inc.			13,649	236,264	0.21%
Immunocore Holdings PLC			7,748	229,883	0.20%
Astellas Pharma, Inc.			23,085	224,721	0.20%
PACS Group, Inc.			19,615	220,473	0.19%

Full Portfolio Holdings* as of March 31, 2025

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Amicus Therapeutics, Inc.			27,015	220,442	0.19%
Celldex Therapeutics, Inc.			12,041	218,544	0.19%
Tecan Group AG			1,120	213,112	0.19%
Ionis Pharmaceuticals, Inc.			6,979	210,556	0.19%
Savara, Inc.			73,505	203,609	0.18%
Nurix Therapeutics, Inc.			16,897	200,736	0.18%
Biogen, Inc.			1,446	197,871	0.17%
Spyre Therapeutics, Inc.			12,222	197,202	0.17%
Rocket Pharmaceuticals, Inc.			24,137	160,994	0.14%
Newamsterdam Pharma Co. NV			7,413	151,744	0.13%
Arcus Biosciences, Inc.			18,606	146,057	0.13%
Janux Therapeutics, Inc.			3,633	98,091	0.09%
FOREIGN CURRENCY					
BRAZILIAN REAL			226,512	39,694	0.03%
SWISS FRANC			35	40	0.00%
EURO CURRENCY			19	21	0.00%
DANISH KRONE			34	5	0.00%
HONG KONG DOLLAR			5	0.58	0.00%
JAPANESE YEN			1	0.01	0.00%
POUND STERLING			(0.16)	(0.21)	0.00%
RIGHTS					
Abiomed, Inc.			885	903	0.00%
SHORT-TERM INVESTMENTS					
Fixed Income Clearing Corp.		4/1/2025	175,164	175,164	0.15%
TOTAL INVESTMENTS				113,434,016	100.00%
OTHER ASSETS LESS LIABILITIES				4,957	0.00%
TOTAL NET ASSETS				113,438,973	100.00%

* This unaudited information is being presented pursuant to the Fund's Policy on Disclosure of Portfolio Holdings. Please see the Fund's Statement of Additional Information on www.hartfordfunds.com for a discussion of the Fund's policy. Holdings are provided for informational purposes only and should not be construed as a recommendation or investment advice. Portfolio holdings are as of the date noted and are subject to change at any time. Holdings may not be representative of current or future investments.

Unlike the Fund's regulatory filings, the portfolio data and its presentation in this document is not required to conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. Therefore, it may differ from that provided in the complete portfolio of investments in the annual and semiannual report to shareholders filed with the SEC on Form N-CSR, and the complete portfolio of investments filed in the first and third quarter on Form N-PORT.

Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the fund's prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

Mutual funds are distributed by Hartford Funds Distributors, LLC, Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC, an SEC registered investment adviser.

227833 03/22